NCT07225556
A Study of LY4167586 in Participants With Obesity or Overweight Who Are Otherwise Healthy
Active, Not Recruiting
PHASE1Ages 18–65InterventionalBasic scienceEli Lilly and Company
~84 participants
Updated 2026-07-29 on ClinicalTrials.gov
What's tested:LY4167586Placebo
At a glance
Recruiting sites
0 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number and Incidence of Serious Adverse Events (SAEs)
Measured over Baseline to study completion (up to 29 weeks)
Conditions
Where it's being run
2 sites across 2 statesWisconsin1
Singapore1
Study leadership
- Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST) · STUDY_DIRECTOR · Eli Lilly and Company
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Participant must be 21 for Singapore site
Have a body mass index (BMI) between 27.0 kilogram per square meter (kg/m²) and 35.0 kg/m², inclusive
Have had a self-reported stable weight for 3 months prior to screening (less than approximately 5 percent \[%\] body weight change)
Exclusion
Have a history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal (GI), endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs, or of constituting a risk when taking the study drug, or of interfering with the interpretation of data.
Is an individual of childbearing potential (IOCBP)
What this trial measures
- Number and Incidence of Serious Adverse Events (SAEs)Baseline to study completion (up to 29 weeks)
A summary of SAEs regardless of causality, will be reported in the Reported Adverse Events module